安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2025-009 证券代码：300009 证券简称：安科生物 | 投资者关系活动 | ☑特定对象调研 □分析师会议 | | --- | --- | | 类别 | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | ☑其他 （电话会议） | | 参与单位名称及 | 华源医药、国盛医药、华福医药、中邮医药、平安证券、华鑫 | | 人员姓名 | 医药、信达医药、华安医药、东吴医药、东方医药、太平资产 | | | 管理、仁桥（北京）资产管理、中信建投基金、优益增投资、 | | | 泰康资产管理、Open Door Investment Management Ltd.、中国国 | | | 际金融、晨岭资本、太朴持信、深圳市尚诚资产管理、高腾国 | | | 际、鸿运私募基金管理、嘉实基金、华泰自营、翼虎投资管理、 | | | 长江养老保险、罗爵资产管理、长城基金管理、昆仑健康、武 | | | 汉证国私募基金、北京金塔股权投资、观合资产、药融圈、杭 | | | 贵投资、北京金百镕投资、上海盟洋投资管理、华宝基金 ...

财务报表中对有大幅变动的财务项目的原因说明如下：短期借款变动幅度为39.92%,原因:子公司安科华 捷本期新增借款。交易性金融资产变动幅度为-34.57%,原因:期初理财产品本期末到期赎回较多。预付款 项变动幅度为219.45%,原因:期末预付的委外研发款项增加较多。其他非流动资产变动幅度为49.77%,原 因:公司生产线建设预付的设备款金额较大。债权投资变动幅度为-56.93%,原因:公司将部分债权投资转 入一年内到期的非流动资产。其他流动负债变动幅度为-51.6%,原因:公司期初确认的应付退货款本期减 少。其他权益工具投资的变动原因:公司作为基石投资者投资维昇药业，投资金额较大。应收款项融资 变动幅度为54.53%,原因:上年同期购买长期资产采取票据支付金额较大。其他流动资产变动幅度 为-78.46%,原因:公司期末预缴企业所得税、增值税留抵税额减少。一年内到期的非流动资产的变动原 因:期末债权投资转入。财务费用变动幅度为352.93%,原因:公司本期计提的汇兑损益金额较大。经营活 动产生的现金流量净额变动幅度为53.75%,原因:上年同期发放2023年末计提的职工薪酬金额较大。 证券之星价投圈财报分析工 ...

Group 1: Company Goals and Strategies - The overall business goal for 2025 is to achieve restorative growth while maintaining stable and healthy development [2] - The company aims to enhance academic promotion and increase the sales proportion of water injections, while pushing for restorative growth in growth hormone sales [2] - The Chinese medicine sector will optimize sales policies for traditional Chinese medicine plasters to maintain growth momentum [2] Group 2: Investment and Partnerships - The cornerstone investment in Weisheng Pharmaceutical is aimed at establishing a long-term cooperative relationship to enhance resource integration and competitive advantage [3] - The company plans to divest forensic-related businesses and actively transition to new business areas [3] Group 3: Sales Performance - In Q1 2025, the sales of growth hormones showed a year-on-year increase, reversing the previous downward trend [3] - The sales revenue of Trastuzumab exceeded 100 million yuan in 2024, with expectations for significant year-on-year growth in 2025 [3] Group 4: Research and Development Progress - The company is advancing several clinical trials, including a new drug targeting HER2, which has shown promising safety and efficacy in early studies [4] - Ongoing clinical trials for various products, including AK1008 and AK1012, are aimed at treating viral infections in children [4] - The company is collaborating on innovative mRNA technology for cancer treatment, with clinical trials approved for AFN0328 injection [4]